Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04295486 · ClinicalTrials.gov registry record · Phase 2

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

A Phase 2 study of Venous Thromboembolism, sponsored by University of Miami.

Recruiting
Registry status
Phase 2
Development phase
5,478
Enrollment target
1
Study location

NCT04295486 is a Phase 2 study of Venous Thromboembolism that is actively recruiting participants, run by University of Miami. The registered enrollment target is 5,478 participants, below the 6,179-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04295486, a Phase 2 study of Venous Thromboembolism, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 2
Development phase
5,478 participants
Enrollment target
1
Study location

Study Summary

This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

Conditions Studied

Interventions

  • DRUG Aspirin

Study Locations (1)

Florida

  • University of Miami Hospital - Miami

Trial Details

FieldValue
Enrollment Target 5,478 participants
Start Date 2021-03-01
Est. Completion 2027-03-01
Phase Phase 2

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT04295486

The ClinicalTrials.gov registry entry for NCT04295486 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 5,478 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,179-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (11% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Aspirin is the first listed.

NCT04295486 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04295486 about?

NCT04295486 is a clinical study titled "Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty". This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

What is the current status of trial NCT04295486?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5,478 participants. The study started on 2021-03-01. Estimated completion is 2027-03-01.

What conditions does trial NCT04295486 study?

This clinical trial studies the following conditions: Venous Thromboembolism.

What interventions are being tested in trial NCT04295486?

The interventions under investigation include: Aspirin (DRUG).

Who is sponsoring clinical trial NCT04295486?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04295486 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Thromboembolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.